DOP2019000097A - Meganucleasas diseñadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b - Google Patents

Meganucleasas diseñadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b

Info

Publication number
DOP2019000097A
DOP2019000097A DO2019000097A DO2019000097A DOP2019000097A DO P2019000097 A DOP2019000097 A DO P2019000097A DO 2019000097 A DO2019000097 A DO 2019000097A DO 2019000097 A DO2019000097 A DO 2019000097A DO P2019000097 A DOP2019000097 A DO P2019000097A
Authority
DO
Dominican Republic
Prior art keywords
meganucleases
hepatitis
designer
specifically designed
virus genome
Prior art date
Application number
DO2019000097A
Other languages
English (en)
Spanish (es)
Inventor
Jantz Derek
Jefferson Smith James
Original Assignee
Prec Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prec Biosciences Inc filed Critical Prec Biosciences Inc
Publication of DOP2019000097A publication Critical patent/DOP2019000097A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DO2019000097A 2016-10-14 2019-04-12 Meganucleasas diseñadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b DOP2019000097A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662408356P 2016-10-14 2016-10-14
US201762452506P 2017-01-31 2017-01-31
US201762527196P 2017-06-30 2017-06-30
US201762527159P 2017-06-30 2017-06-30

Publications (1)

Publication Number Publication Date
DOP2019000097A true DOP2019000097A (es) 2019-07-31

Family

ID=60480360

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2019000097A DOP2019000097A (es) 2016-10-14 2019-04-12 Meganucleasas diseñadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b

Country Status (21)

Country Link
US (6) US10662416B2 (cg-RX-API-DMAC7.html)
EP (2) EP3526323B1 (cg-RX-API-DMAC7.html)
JP (5) JP6811857B2 (cg-RX-API-DMAC7.html)
KR (4) KR20210118240A (cg-RX-API-DMAC7.html)
CN (2) CN117402852A (cg-RX-API-DMAC7.html)
AU (2) AU2017342536A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019007450A2 (cg-RX-API-DMAC7.html)
CA (1) CA3040143A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019000993A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019003675A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190181A (cg-RX-API-DMAC7.html)
DK (1) DK3526323T5 (cg-RX-API-DMAC7.html)
DO (1) DOP2019000097A (cg-RX-API-DMAC7.html)
FI (1) FI3526323T3 (cg-RX-API-DMAC7.html)
IL (3) IL265921B2 (cg-RX-API-DMAC7.html)
MA (1) MA46535A (cg-RX-API-DMAC7.html)
MX (2) MX2019004349A (cg-RX-API-DMAC7.html)
PE (1) PE20191353A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019500788A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201914029RA (cg-RX-API-DMAC7.html)
WO (1) WO2018071849A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210118240A (ko) 2016-10-14 2021-09-29 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2020227534A1 (en) 2019-05-07 2020-11-12 Precision Biosciences, Inc. Optimization of engineered meganucleases for recognition sequences
IL315295A (en) 2019-09-30 2024-10-01 Gilead Sciences Inc Hbv vaccines and methods treating hbv
CN116057068A (zh) 2019-12-06 2023-05-02 精密生物科学公司 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021231259A1 (en) 2020-05-11 2021-11-18 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR102826438B1 (ko) * 2020-11-12 2025-07-04 프리시젼 바이오사이언시스 인코포레이티드 디스트로핀 유전자 내의 인식 서열에 대해 특이성을 갖는 조작된 메가뉴클레아제
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2025049788A1 (en) 2023-08-29 2025-03-06 The Broad Institute, Inc. Optical genetic screens of intracellular and intercellular transcriptional circuits with perturb-fish
WO2025096916A1 (en) 2023-11-03 2025-05-08 The Broad Institute, Inc. Multi-site editing in living cells
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection

Family Cites Families (272)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
JPH07502653A (ja) 1991-12-23 1995-03-23 カイロン　コーポレイション 溶液相サンドイッチハイブリダイゼーションアッセイに用いるためのｈｂｖ増幅プローブ
EP1288296A3 (en) * 1992-05-11 2003-03-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting HBV viral replication
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
CN1204248C (zh) * 2002-02-05 2005-06-01 中国人民解放军第四军医大学 治疗乙肝病毒感染的靶向核糖核酸酶的制备工艺
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
ATE549401T1 (de) * 2005-10-18 2012-03-15 Prec Biosciences Rational konstruierte meganukleasen mit veränderter sequenzspezifität und dna- bindungsaffinität
JP4235837B2 (ja) 2006-04-04 2009-03-11 セイコーエプソン株式会社 粒状性の予測、プロファイルの作成および印刷装置
US8338593B2 (en) 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
WO2009001159A1 (en) 2007-06-25 2008-12-31 Cellectis Method for enhancing the cleavage activity of i-crei derived meganucleases
US8748373B2 (en) * 2007-02-21 2014-06-10 Fox Chase Cancer Center Hepatitis B virus compositions and methods of use
CN101784548B (zh) 2007-06-29 2013-07-17 吉里德科学公司 嘌呤衍生物及其作为toll样受体7的调节剂的用途
ES2422291T3 (es) 2007-10-31 2013-09-10 Prec Biosciences Inc Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
JP5749494B2 (ja) 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション 核酸の送達のための改善された組成物および方法
NO2824100T3 (cg-RX-API-DMAC7.html) 2008-07-08 2018-07-21
PT2313111E (pt) 2008-08-01 2013-12-05 Ventirx Pharmaceuticals Inc Formulações de agonista de receptor do tipo toll e seus usos
EA021377B9 (ru) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
WO2010136841A2 (en) * 2009-05-26 2010-12-02 Cellectis Meganuclease variants cleaving the genome of a non-genomically integrating virus and uses thereof
WO2010136981A2 (en) 2009-05-26 2010-12-02 Cellectis Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
DK2467380T3 (en) 2009-08-18 2017-03-13 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS
JP5756804B2 (ja) 2009-08-18 2015-07-29 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｔｏｌｌ様レセプターモジュレーターとしての置換ベンゾアゼピン
IN2012DN02984A (cg-RX-API-DMAC7.html) 2009-10-22 2015-07-31 Gilead Sciences Inc
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
BR112012030711B1 (pt) 2010-05-31 2020-10-13 Ono Pharmaceutical Co. Ltd derivado de purinona
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
MX340290B (es) 2010-10-01 2016-07-04 Ventirx Pharmaceuticals Inc Uso terapéutico de un agonista de receptor tipo toll y terapia de combinación.
WO2012045089A2 (en) 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Methods for the treatment of allergic diseases
AR084217A1 (es) 2010-12-10 2013-05-02 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
PL2663550T3 (pl) 2011-01-12 2017-07-31 Ventirx Pharmaceuticals, Inc. Podstawione benzoazepiny jako modulatory receptora toll-podobnego
HUE032638T2 (en) 2011-01-12 2017-10-30 Ventirx Pharmaceuticals Inc Toll receptor modulator substituted benzoazepines
MA34956B1 (fr) 2011-02-12 2014-03-01 Globeimmune Inc Therapeutique a base de levure pour infection chronique par l'hepatite b
EP3330257B1 (en) 2011-04-08 2020-03-11 Janssen Sciences Ireland Unlimited Company Pyrimidine derivatives for the treatment of viral infections
AU2012258220B2 (en) 2011-05-18 2017-01-19 Janssen Sciences Ireland Uc Quinazoline derivatives for the treatment of viral infections and further diseases
WO2012167192A2 (en) 2011-06-01 2012-12-06 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
CN103732238A (zh) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 用于免疫调节的治疗性化合物
EA202191537A1 (ru) * 2011-06-30 2022-01-31 Эрроухэд Фармасьютикалс, Инк. Композиции и способы ингибирования экспрессии генов вируса гепатита в
WO2013006841A1 (en) * 2011-07-06 2013-01-10 Yale University Stimulation of arterial collateral growth and lymphogenesis
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
WO2013096744A1 (en) 2011-12-21 2013-06-27 Novira Therapeutics, Inc. Hepatitis b antiviral agents
JP6283320B2 (ja) 2012-02-08 2018-02-21 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体
CN104159911A (zh) 2012-03-07 2014-11-19 奥瑞基尼探索技术有限公司 作为免疫调节剂的模拟肽化合物
AU2013239366A1 (en) 2012-03-29 2014-10-16 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the BC loop of human PD1
WO2013144129A1 (en) 2012-03-31 2013-10-03 F. Hoffmann-La Roche Ag Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
US9090653B2 (en) 2012-06-08 2015-07-28 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
IN2014MN02652A (cg-RX-API-DMAC7.html) 2012-06-08 2015-08-21 Gilead Sciences Inc
SG11201500814UA (en) 2012-08-10 2015-03-30 Janssen Sciences Ireland Uc Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
AU2013307331A1 (en) 2012-08-28 2015-02-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B
SG11201501360TA (en) 2012-08-28 2015-03-30 Janssen Sciences Ireland Uc Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
BR112015004113A2 (pt) 2012-09-10 2017-07-04 Hoffmann La Roche 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
DK2903968T3 (en) 2012-10-02 2017-01-30 Gilead Sciences Inc INHIBITORS OF HISTON DEMETHYLASES
EP2906563B1 (en) 2012-10-10 2018-02-28 Janssen Sciences Ireland UC Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
CA2886635C (en) 2012-11-16 2021-01-05 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
MX2015007205A (es) 2012-12-06 2016-03-31 Quanticel Pharmaceuticals Inc Inhibidores de la desmetilasa de histona.
LT2934145T (lt) 2012-12-19 2018-02-26 Celgene Quanticel Research, Inc. Histono demetilazės inhibitoriai
KR20150100814A (ko) 2012-12-21 2015-09-02 콴티셀 파마슈티컬스, 인크. 히스톤 데메틸라제 억제제
ES2733361T3 (es) 2013-02-21 2019-11-28 Janssen Sciences Ireland Unlimited Co Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas
EP3170811A1 (en) 2013-02-27 2017-05-24 Gilead Sciences, Inc. Ethyl pyridine-4-carboxylate compound as inhibitor of histone demethylases
PT2961732T (pt) 2013-02-28 2017-06-26 Janssen Sciences Ireland Uc Sulfamoil-arilamidas e utilização das mesmas como medicamentos para o tratamento de hepatite b
EP2968282B1 (en) 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
MX2015011898A (es) 2013-03-13 2016-05-05 Genentech Inc Compuestos de pirazolo y usos de los mismos.
CA2903081A1 (en) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
EP2970211B1 (en) 2013-03-15 2017-07-26 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
EA027068B1 (ru) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
CN105960400B (zh) 2013-05-17 2019-05-31 爱尔兰詹森科学公司 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
PE20151951A1 (es) 2013-05-17 2015-12-26 Hoffmann La Roche Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
AU2014294997B2 (en) 2013-07-25 2018-03-22 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3027624B1 (en) 2013-07-30 2018-09-12 Janssen Sciences Ireland UC Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
JP2016527303A (ja) 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害
WO2015023958A1 (en) 2013-08-15 2015-02-19 The University Of Kansas Toll-like receptor agonists
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
EA031325B1 (ru) 2013-09-06 2018-12-28 Ауриген Дискавери Текнолоджиз Лимитед Циклические пептидомиметические соединения в качестве иммуномодуляторов
PL3041828T3 (pl) 2013-09-06 2018-10-31 Aurigene Discovery Technologies Limited Pochodne 1,3,4-oksadiazolu i 1,3,4-tiadiazolu jako immunomodulatory
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
AU2014320463B2 (en) 2013-09-11 2018-08-02 Centre National De La Recherche Scientifique (Cnrs) Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
MY192489A (en) 2013-10-14 2022-08-23 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
WO2015057655A1 (en) 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
WO2015073774A1 (en) 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis b infections
WO2015089465A1 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
US9643967B2 (en) 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
WO2015095780A1 (en) 2013-12-20 2015-06-25 The University Of Kansas Toll-like receptor 8 agonists
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
AU2015212903A1 (en) 2014-01-30 2016-05-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection
PH12020550847A1 (en) 2014-02-04 2022-05-11 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
UY35980A (es) 2014-02-06 2015-08-31 Janssen Sciences Ireland Uc Derivados de sulfamoilpirrolamida como inhibidores del hbv y composiciones farmacéuticas que los contienen
WO2015134605A1 (en) 2014-03-05 2015-09-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
CN109232613A (zh) 2014-03-07 2019-01-18 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的6-稠合的杂芳基二氢嘧啶
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
PT3134402T (pt) 2014-04-22 2020-07-02 Hoffmann La Roche Compostos de 4-amino-imidazoquinolina
US9944649B2 (en) 2014-05-01 2018-04-17 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
MX362341B (es) 2014-05-01 2019-01-11 Novartis Ag Compuestos y composiciones como agonistas del receptor tipo toll 7.
CA2948080A1 (en) 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
CA2949961C (en) 2014-05-23 2023-09-19 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
US20160060655A1 (en) 2014-05-30 2016-03-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods to treat latent viral infections
CA2951259A1 (en) 2014-06-06 2015-12-10 Flexus Biosciences, Inc. Immunoregulatory agents
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
WO2016019232A1 (en) 2014-08-01 2016-02-04 John Vasilakos Methods and therapeutic combinations for treating tumors
RU2664329C1 (ru) 2014-08-14 2018-08-16 Ф. Хоффманн-Ля Рош Аг Новые пиридазоны и триазиноны для лечения и профилактики заражения вирусом гепатита b
MX386981B (es) 2014-08-15 2025-03-19 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
WO2016029077A1 (en) 2014-08-22 2016-02-25 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
CN107074807A (zh) 2014-08-27 2017-08-18 吉利德科学公司 用于抑制组蛋白脱甲基酶的组合物和方法
US9884866B2 (en) 2014-09-08 2018-02-06 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
EP3191113B1 (en) 2014-09-11 2019-11-06 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-l1 protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
JP6783230B2 (ja) 2014-10-10 2020-11-11 ジェネンテック， インコーポレイテッド ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
WO2016055553A1 (en) 2014-10-11 2016-04-14 F. Hoffmann-La Roche Ag Compounds for use in the treatment of infectious diseases
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
EA201790806A1 (ru) 2014-11-05 2017-11-30 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
US10584125B2 (en) 2014-11-13 2020-03-10 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
CN107445980B (zh) 2014-12-08 2021-04-20 豪夫迈·罗氏有限公司 3-取代的5-氨基-6H-噻唑并[4,5-d]嘧啶-2,7-二酮化合物
CN107148417B (zh) 2014-12-18 2020-09-08 豪夫迈·罗氏有限公司 苯并氮杂*磺酰胺化合物
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
JP6713465B2 (ja) 2014-12-30 2020-06-24 ノヴィラ・セラピューティクス・インコーポレイテッド Ｂ型肝炎感染症治療のための誘導体及び方法
JP6506845B2 (ja) 2014-12-30 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療及び予防のための新規テトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
JP2018504891A (ja) 2014-12-31 2018-02-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ リアルタイムＰＣＲによる細胞溶解物からのＨＢＶ ｃｃｃＤＮＡ定量化のための新規ハイスループット法
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
JP2018502604A (ja) 2015-01-27 2018-02-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 組換えＨＢＶ ｃｃｃＤＮＡ、その作製方法およびその使用
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
WO2016128335A1 (en) 2015-02-11 2016-08-18 F. Hoffmann-La Roche Ag Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
MY199988A (en) 2015-03-04 2023-12-02 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
UA121887C2 (uk) 2015-03-06 2020-08-10 Ф. Хоффманн-Ля Рош Аг Сполуки бензазепіну дикарбоксаміду
BR112017019307A2 (pt) 2015-03-10 2018-05-02 Aurigene Discovery Technologies Limited compostos de 1,3,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
CU20170120A7 (es) 2015-03-10 2018-06-05 Aurigene Discovery Tech Ltd Compuestos 3-sustituidos de 1 de 1,3,4-oxadiazol y tiadiazol como inmunomoduladores
MX2017011617A (es) 2015-03-10 2018-03-23 Aurigene Discovery Tech Ltd Compuestos cíclicos terapéuticos como inmunomoduladores.
AU2016230759A1 (en) 2015-03-10 2017-09-07 Aurigene Discovery Technologies Limited 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
EP4023645A1 (en) 2015-03-10 2022-07-06 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3283472B1 (en) 2015-04-17 2021-04-14 Indiana University Research & Technology Corporation Hepatitis b viral assembly effectors
JP6462155B2 (ja) 2015-05-04 2019-01-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療用のＨＢｓＡｇ（ＨＢＶ表面抗原）及びＨＢＶ ＤＮＡ産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
WO2016180743A1 (en) 2015-05-12 2016-11-17 F. Hoffmann-La Roche Ag Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
US10196701B2 (en) 2015-06-01 2019-02-05 The Penn State Research Foundation Hepatitis B virus capsid assembly
GB201511477D0 (en) 2015-06-30 2015-08-12 Redx Pharma Plc Antiviral compounds
JP6839104B2 (ja) 2015-06-30 2021-03-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017007701A1 (en) 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
JP6598974B2 (ja) 2015-07-21 2019-10-30 エフ．ホフマン−ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症の治療および予防のための新規な三環式４−ピリドン−３−カルボン酸誘導体
WO2017016960A1 (en) 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
JP6506880B2 (ja) 2015-07-27 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体
CN107835813B (zh) 2015-07-28 2020-04-24 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的6,7-二氢吡啶并[2,1-a]酞嗪-2-酮类化合物
KR20180030911A (ko) 2015-07-29 2018-03-26 노파르티스 아게 Pd-1 길항제와 egfr 억제제의 조합물
AU2016305941B2 (en) 2015-08-10 2018-11-15 Merck Sharp & Dohme Llc Antiviral beta-amino acid ester phosphodiamide compounds
HK1249109A1 (zh) 2015-08-13 2018-10-26 Merck Sharp & Dohme Corp. 作为sting激动剂的环状二核苷酸化合物
US11130736B2 (en) 2015-08-21 2021-09-28 University Of Kansas Human TLR8-selective agonists
WO2017038909A1 (en) 2015-08-28 2017-03-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds
US10150768B2 (en) 2015-08-31 2018-12-11 3M Innovative Properties Company Guanidine substituted imidazo[4,5-c] ring compounds
TWI721016B (zh) 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
WO2017047769A1 (ja) 2015-09-17 2017-03-23 国立大学法人富山大学 トール様受容体７またはトール様受容体９の活性化阻害剤
WO2017046112A1 (en) 2015-09-17 2017-03-23 F. Hoffmann-La Roche Ag Sulfinylphenyl or sulfonimidoylphenyl benzazepines
WO2017061466A1 (ja) 2015-10-05 2017-04-13 富山化学工業株式会社 抗ｂ型肝炎ウイルス剤
ES2960724T3 (es) 2015-10-07 2024-03-06 Sumitomo Pharma Co Ltd Composición que comprende un compuesto de pirimidina y un antígeno derivado de patógeno
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
EP3368072A4 (en) 2015-10-28 2019-07-03 Aduro BioTech, Inc. COMPOSITIONS AND METHOD FOR ACTIVATING SIGNALING DEPENDENT ON THE STIMULATOR OF THE INTERFERON GENE
HRP20221474T1 (hr) 2015-11-04 2023-01-06 Hookipa Biotech Gmbh Cjepiva protiv virusa hepatitisa b
WO2017079669A1 (en) 2015-11-04 2017-05-11 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
ES2833927T3 (es) 2015-11-05 2021-06-16 Chai Tai Tianqing Pharmaceutical Group Co Ltd Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de TLR7
JP6983776B2 (ja) 2015-11-19 2021-12-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
CA3005727A1 (en) 2015-11-19 2017-05-26 Incyte Corporation Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators
ES2863225T3 (es) 2015-12-03 2021-10-11 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos purinos como moduladores del sting
EP3386512B1 (en) 2015-12-10 2023-11-22 Merck Sharp & Dohme LLC Antiviral phosphodiamide prodrugs of tenofovir
WO2017106740A1 (en) 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
TW201726623A (zh) 2015-12-17 2017-08-01 英塞特公司 作為免疫調節劑之雜環化合物
MX385424B (es) 2015-12-17 2025-03-18 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
CR20180374A (es) 2015-12-22 2018-10-16 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
CA3009637A1 (en) * 2015-12-23 2017-06-29 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
UY37128A (es) 2016-02-19 2017-09-29 Novartis Ag Compuestos tetracíclicos de piridona como antivirales
SG10201912074PA (en) 2016-03-18 2020-02-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
WO2017163264A1 (en) 2016-03-21 2017-09-28 Council Of Scientific & Industrial Research Blocking toll-like receptor 9 signaling with small molecule antagonist
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US10556903B2 (en) 2016-04-19 2020-02-11 Innate Tumor Immunity, Inc. NLRP3 modulators
WO2017184735A1 (en) 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
AU2017260426B2 (en) * 2016-05-03 2023-08-31 Precision Biosciences, Inc. Engineered nucleases useful for treatment of hemophilia A
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
LT3453707T (lt) 2016-05-06 2022-03-10 Shanghai De Novo Pharmatech Co., Ltd. Benzazepino darinys, gamybos būdas, farmacinė kompozicija ir jos naudojimas
EP3458455B1 (en) 2016-05-20 2021-06-16 F. Hoffmann-La Roche AG Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
EP3464274B1 (en) 2016-05-23 2020-05-27 H. Hoffnabb-La Roche Ag Benzazepine dicarboxamide compounds with secondary amide function
CN109153648B (zh) 2016-05-23 2022-07-22 豪夫迈·罗氏有限公司 具有叔酰胺官能团的苯并氮杂卓二甲酰胺化合物
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3464278B1 (en) 2016-05-26 2021-06-16 F. Hoffmann-La Roche AG Xanthone derivatives for the treatment and prophylaxis of hepatitis b virus disease
WO2017211791A1 (en) 2016-06-07 2017-12-14 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and a tlr7 agonist
SG11201810834WA (en) 2016-06-10 2018-12-28 Enanta Pharm Inc Hepatitis b antiviral agents
JP7012668B2 (ja) 2016-06-12 2022-02-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
CA3028685A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017219931A1 (zh) 2016-06-22 2017-12-28 四川科伦博泰生物医药股份有限公司 二氢蝶啶酮类衍生物、其制备方法及其用途
JP6821716B2 (ja) 2016-06-29 2021-01-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染の処置および予防のための新規のジヒドロピロロピリミジン
WO2018005881A1 (en) 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections
CN109311880B (zh) 2016-06-29 2021-09-03 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的四氢吡啶并嘧啶类化合物
MA45550A (fr) 2016-06-29 2019-05-08 Novira Therapeutics Inc Dérivés de diazépinone et leur utilisation dans le traitement des infections par l'hépatite b
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
KR102468272B1 (ko) 2016-06-30 2022-11-18 삼성전자주식회사 음향 출력 장치 및 그 제어 방법
CN109476675B (zh) 2016-07-01 2022-12-09 爱尔兰詹森科学公司 用于治疗病毒性感染的二氢吡喃并嘧啶衍生物
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JP7168551B2 (ja) 2016-07-08 2022-11-09 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤として有用な１，３－ジヒドロキシフェニル誘導体
EP3484885B1 (en) 2016-07-14 2020-03-04 H. Hoffnabb-La Roche Ag Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
WO2018011160A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
EP3484886B1 (en) 2016-07-14 2020-03-04 Hoffmann-La Roche AG 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
WO2018011100A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag Novel tetrahydropyrazolopyridine compounds for the treatment of infectious diseases
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018019297A1 (zh) 2016-07-29 2018-02-01 银杏树药业(苏州)有限公司 异喹啉酮类化合物及其制备抗病毒药物的应用
WO2018022282A1 (en) 2016-07-29 2018-02-01 Newave Pharmaceutical Inc. Novel therapeutic agents for the treatment of hbv infection
KR102506321B1 (ko) 2016-07-30 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 Tlr7, tlr8 또는 tlr9 억제제로서의 디메톡시페닐 치환된 인돌 화합물
CA3030773A1 (en) 2016-08-03 2018-02-08 Arising International, Inc. Symmetric or semi-symmetric compounds useful as immunomodulators
KR20240019867A (ko) 2016-08-08 2024-02-14 메르크 파텐트 게엠베하 Tlr7/8 안타고니스트 및 이의 용도
JP2019526562A (ja) 2016-08-24 2019-09-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｂｖキャプシドアセンブリ阻害剤とヌクレオシ（チ）ド類似体の併用療法
US10414779B2 (en) 2016-08-26 2019-09-17 3M Innovative Properties Company Fused [1,2]imidazo[4,5-C] ring compounds substituted with guanidino groups
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
MA46093A (fr) 2016-09-02 2021-05-19 Gilead Sciences Inc Composés modulateurs du recepteur de type toll
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
WO2018043747A1 (ja) 2016-09-05 2018-03-08 国立大学法人京都大学 抗ｂ型肝炎ウイルス剤
US11274115B2 (en) 2016-09-07 2022-03-15 Glaxosmithkline Biological Sa Imidazoquinoline derivatives and their use in therapy
WO2018049089A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
PE20190732A1 (es) 2016-09-09 2019-05-23 Novartis Ag Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
CN109803967B (zh) 2016-09-09 2022-05-24 浙江海正药业股份有限公司 二氢嘧啶类化合物及其制备方法和用途
WO2018051254A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
WO2018051255A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
SI3523287T1 (sl) 2016-10-04 2021-11-30 Merck Sharp & Dohme Corp. Benzo(b)tiofenske spojine kot agonisti STING
US11001605B2 (en) 2016-10-07 2021-05-11 Biolog Life Science Institute Gmbh & Co. Kg Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
KR20210118240A (ko) 2016-10-14 2021-09-29 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
KR20190067235A (ko) 2016-10-20 2019-06-14 오리진 디스커버리 테크놀로지스 리미티드 Vista 및 pd-1 경로의 이중 억제제
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
WO2018078149A1 (en) 2016-10-31 2018-05-03 F. Hoffmann-La Roche Ag Novel cyclicsulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
US10988507B2 (en) 2016-11-07 2021-04-27 Bristol-Myers Squibb Company Immunomodulators
WO2018089695A1 (en) 2016-11-11 2018-05-17 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
US11084818B2 (en) 2016-11-11 2021-08-10 Hepo Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
KR20190084991A (ko) 2016-11-28 2019-07-17 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피라졸로-헤테로아릴 유도체, 이의 제조 방법 및 의학적 용도
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
JP7106572B2 (ja) 2016-12-20 2022-07-26 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤として有用な化合物
JP2020511420A (ja) 2016-12-20 2020-04-16 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんの処置のためのｐｄ−１アンタゴニストと環状ジヌクレオチドｓｔｉｎｇアゴニストとの組み合わせ
RU2019122598A (ru) 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
TW201829412A (zh) 2016-12-22 2018-08-16 美商默沙東藥廠 抗病毒之替諾福韋（tenofovir）之脂系酯前藥
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US11123355B2 (en) 2016-12-22 2021-09-21 Idenix Pharmaceuticals Llc Antiviral benzyl-amine phosphodiamide compounds
JP7303108B2 (ja) 2016-12-22 2023-07-04 インサイト・コーポレイション 免疫調節剤としての二環式複素芳香環化合物
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
CR20190318A (es) 2016-12-22 2019-10-21 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2018199338A1 (ja) 2017-04-27 2018-11-01 国立大学法人広島大学 Ｂ型肝炎治療用核酸分子
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome

Also Published As

Publication number Publication date
IL265921A (en) 2019-06-30
US20250154486A1 (en) 2025-05-15
JP2019530462A (ja) 2019-10-24
DK3526323T5 (da) 2024-09-02
US20200239864A1 (en) 2020-07-30
MA46535A (fr) 2019-08-21
DK3526323T3 (da) 2023-06-26
JP2025138637A (ja) 2025-09-25
EP3526323B1 (en) 2023-03-29
EP3526323A2 (en) 2019-08-21
EP4234691A2 (en) 2023-08-30
US10662416B2 (en) 2020-05-26
CN117402852A (zh) 2024-01-16
JP6919049B2 (ja) 2021-08-11
CO2019003675A2 (es) 2019-04-30
IL265921B1 (en) 2024-01-01
BR112019007450A2 (pt) 2020-07-07
JP2023153824A (ja) 2023-10-18
IL308894A (en) 2024-01-01
EP4234691A3 (en) 2023-10-18
US10851358B2 (en) 2020-12-01
KR20230010826A (ko) 2023-01-19
US20240271111A1 (en) 2024-08-15
KR20210118240A (ko) 2021-09-29
MX2019004349A (es) 2019-09-26
WO2018071849A2 (en) 2018-04-19
JP6811857B2 (ja) 2021-01-13
KR20190064628A (ko) 2019-06-10
IL265921B2 (en) 2024-05-01
SG10201914029RA (en) 2020-03-30
PE20191353A1 (es) 2019-10-01
AU2017342536A1 (en) 2019-05-02
CL2019000993A1 (es) 2019-08-30
KR20240123417A (ko) 2024-08-13
SG11201903042VA (en) 2019-05-30
AU2023263542A1 (en) 2023-11-30
WO2018071849A3 (en) 2018-05-24
CN110023495A (zh) 2019-07-16
IL317537A (en) 2025-02-01
US20190284543A1 (en) 2019-09-19
PH12019500788A1 (en) 2019-11-11
US20220243187A1 (en) 2022-08-04
MX2024001134A (es) 2024-02-27
US20210180038A1 (en) 2021-06-17
US11274285B2 (en) 2022-03-15
CA3040143A1 (en) 2018-04-19
KR102305215B1 (ko) 2021-09-28
FI3526323T3 (fi) 2023-06-06
JP2021061841A (ja) 2021-04-22
CR20190181A (es) 2019-08-21
JP2021180665A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
DOP2019000097A (es) Meganucleasas diseñadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b
AR115041A1 (es) Meganucleasas optimizadas diseñadas mediante ingeniería que poseen especificidad para una secuencia de reconocimiento en el genoma del virus de la hepatitis b
CL2019000621A1 (es) Oligómeros y conjugados de oligómeros (divisional solicitud 201602849)
UY37699A (es) Compuestos fusionados de indazol piridona como antivirales
PH12018500573A1 (en) Hepatitis b core protein modulators
MX2022003658A (es) Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
UY37961A (es) Nuevas y altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
EA201390538A1 (ru) Противовирусные соединения
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
UY37962A (es) Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
EA201790160A1 (ru) Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
BR112014013972A2 (pt) inibidores de hcv nssa
CL2013000670A1 (es) Metodo para tratar una infeccion por virus de la hepatitis c (hcv) que comprende admninistrar un inhibidor de la serina proteasa ns3 del hvc, un inhibidor de la arn polimerasa dependiente de arn ns5b de hcv y opcionalmente ribavirina; composicion farmaceutica; estuche; y su uso de para el tratamiento de una infeccion por hcv.
CL2018001946A1 (es) Virus atenuados de bronquitis infecciosa.
BR112014015582A2 (pt) compostos antivirais
MX2022002231A (es) Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b.
EP4567109A3 (en) Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
PH12020551944A1 (en) Reverse peptide vaccine
EA201692514A1 (ru) Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением
EA201790778A1 (ru) Фармацевтические композиции длительного действия от гепатита с
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201990792A1 (ru) Сконструированные мегануклеазы, специфичные к последовательностям распознавания в геноме вируса гепатита b
Ghosh et al. Cytoskeletal proteins: Shaping progression of hepatitis c virus-induced liver disease